Both the genetic knock-down of SHMT2 and treatment with an SHMT inhibitor inhibited the proliferation and migration of undifferentiated thyroid cancer cells and significantly reduced tumor growth in ATC in vivo. This evidence concerns the gene SHMT1 and thyroid gland carcinoma.